BioCentury | Feb 7, 2020
Translation in Brief

Gilead’s remdesivir vs. 2019-nCov in cells; plus Syndax, Syntrix and Max Planck

Chinese team provides data for Gilead’s remdesivir against 2019-nCoV  A group from the Chinese Academy of Science’s Wuhan Institute of Virology and the Beijing Institute of Pharmacology and Toxicology showed that remdesivir reduced 2019-nCoV infection...
BioCentury | Jan 17, 2020
Targets & Mechanisms

CPSF3 emerges as new synthetic lethality target in AML and sarcoma

A team led by the Novartis Institutes for BioMedical Research identified CPSF3, a pre-mRNA processing endonuclease, as a novel synthetic lethality target for a subset of AML and sarcomas. The premise of synthetic lethality is...
BioCentury | Oct 15, 2019
Finance

Cyteir synthetic lethality compound prompts Novo to lead $40M investment

After bringing its lead candidate to the clinic, Cyteir raised $40.2 million in a series B extension to propel the first-in-class RAD51 inhibitor to clinical proof of concept and enable the development of a second...
BC Innovations | Sep 12, 2019
Distillery Techniques

Beam co-founder describes base editors with reduced RNA editing

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Gene therapy Beam Therapeutics co-founder J. Keith Joung and colleagues described cytosine and adenine base editors that could reduce off-target RNA editing compared with prior versions of the technologies. An...
BC Extra | Jul 1, 2019
Company News

Long wait cost Pfizer until BEACON data clinched Array deal

By waiting for a crucial clinical readout that arrived in May 2019, Pfizer watched Array's stock price climb for two years, eventually paying a takeout price that was well over four times the biotech's value...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BC Extra | Oct 10, 2018
Preclinical News

In utero base editing corrects metabolic birth defect

Researchers from Children's Hospital of Philadelphia and University of Pennsylvania opened the door to prenatal genome editing by using a relatively new CRISPR-based approach called base editor 3 to correct tyrosinemia type I, a rare...
BC Week In Review | Apr 13, 2018
Company News

Novo Nordisk licenses sickle cell candidate from EpiDestiny

EpiDestiny Inc. (Solon, Ohio) granted Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) exclusive, worldwide rights to EPI01 to treat sickle cell disease (SCD) and beta-thalassemia. EpiDestiny is eligible for more than $400 million, comprising a $12 million...
BC Extra | Apr 5, 2018
Company News

Novo in deal for EpiDestiny's hematology candidate

EpiDestiny Inc. (Solon, Ohio) granted Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) exclusive, worldwide rights to EPI01 to treat sickle cell disease (SCD) and beta-thalassemia. EpiDestiny is eligible for more than $400 million, comprising a $12 million...
BC Innovations | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
Items per page:
1 - 10 of 41